(153 days)
Not Found
No
The description focuses on software-controlled electrical pulse delivery based on clinician-chosen parameters and hardware safety features. There is no mention of AI or ML algorithms for decision-making, image analysis, or parameter optimization.
Yes
The device is indicated for the surgical ablation of soft tissue, which is a therapeutic intervention.
No
The device is described as an "ablation" system for "surgically ablat[ing] soft tissue," which is a treatment modality, not a diagnostic one. While it mentions confirming ablation success using "standard imaging techniques," these techniques are external to the device and used post-procedure, not for diagnosis by the device itself.
No
The device description explicitly states it is a "software-controlled low-energy direct-current (LEDC) generator" and includes hardware components like "Single Electrode Probes" and a "Probe Spacer." The performance studies also detail hardware-specific testing.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "surgical ablation of soft tissue." This is a therapeutic procedure performed directly on the patient's body.
- Device Description: The device is a generator that delivers electrical current to ablate tissue. This is a physical intervention, not a test performed on a sample taken from the body.
- Lack of IVD Characteristics: IVD devices are used to examine specimens (like blood, urine, tissue samples) taken from the human body to provide information for diagnosis, monitoring, or treatment. This device does not perform any such examination of a specimen.
The NanoKnife System is a therapeutic medical device used for surgical intervention.
N/A
Intended Use / Indications for Use
The NanoKnife System with six outputs is indicated for the surgical ablation of soft tissue.
Product codes
OAB
Device Description
The NanoKnife System is a software-controlled low-energy direct-current (LEDC) generator which surgically ablates soft tissue. Included for use with the system are the NanoKnife Single Electrode Probes and optional Probe Spacer. With the NanoKnife System, electrical current is delivered between pairs of probes in a series of pulses. The waveform of the current is adjustable as determined by clinician-chosen parameters. These parameters include volts/cm, pulse length, number of pulses to be delivered between electrode pairs, distance between probes, and the timing mode (90PPM, 240PPM or ECG synchronization). Up to six probes may be placed in an array within the tissue. The array are matched as pairs by the system. When probes are activated via a foot-pedal, the scheduled current is delivered to tissue between subsequent pairs of probes. Soft tissue between the probes is ablated.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
soft tissue
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The modified NanoKnife System Generator was tested per the following to support a determination of substantial equivalence:
- Performance testing, including: ECG synchronization operation, Power supply regulation, AC/DC board voltages, Charge bank verification, Hardware safety measures (i.e., over/under current pulse intervention, overlength pulse, O Field Programmable Gate Array firmware functionality, etc.), Voltage and current accuracy, Pulse duration, Minimum capacitance, Pulse amplitude, Pulse frequency, Pulse intervals, Pulse count, Maximum energy delivered, Emergency Stop Button functionality
- Ship testing environmental and vibration/handling
- Reliability testing
- EMC testing (EN 60601-1-2:2001/A1:2006)
- Electrical safety testing (IEC 60601-1-2:2001/A1:2004)
- Software validation testing
The test results verify that the NanoKnife System meets all the specified performance specifications and thus, is substantially equivalent to the predicate device. Additionally, AngioDynamics performed a series of ablation and thermal zone calculations with physical parameters input to the Pennes bioheat model utilizing an industry standard differential equation and finite element analysis tool for physics and biological systems. The results of worst-case modeling indicate that potential thermal ablation volumes lie within the boundaries of electroporation volumes where clinically-relevant input parameters are utilized.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4400 Electrosurgical cutting and coagulation device and accessories.
(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized design of three human profiles facing right, with flowing lines representing hair or clothing. The profiles are arranged in a way that creates a sense of depth and connection. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the design.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 18, 2015
Angiodynamics Incorporated Ms. Suzanne Goodman Senior Regulatory Affairs Manager 26 Forest Street Marlborough, Massachusetts 01752
Re: K150089
Trade/Device Name: NanoKnife System Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: Class II Product Code: OAB Dated: May 18, 2015 Received: May 19, 2015
Dear Ms. Goodman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Jennifer R. Stevenson -S
For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K150089
Device Name NanoKnife System
Indications for Use (Describe)
The NanoKnife System with six outputs is indicated for the surgical ablation of soft tissue.
Type of Use (Select one or both, as applicable)
× Prescription Use (Part 21 CFR 801 Subpart D) D Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda. hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
K150089 Page 1 of 4
510(k) Summary - NanoKnife System
Date Prepared: 16 January, 2015
A. Sponsor
AngioDynamics, Inc. 603 Queensbury Avenue Queensbury Avenue Queensbury, NY 12804
B. Contact
Suzanne Goodman Senior Regulatory Affairs Manager AngioDynamics, Inc. 26 Forest Street Marlborough, MA 01752 508-658-7942
C. Device Name
Trade Name: NanoKnife System Common/Usual Name: Low energy direct current ablation device Classification Name: 21 CFR 878.4400, Electrosurgical Cutting and Coagulation Device and Accessories OAB Product Code: : D. Predicate Device(s) Trade Name: NanoKnife System (K102329)
Common/Usual Name: Classification Name:
Classification Panel:
Low energy direct current ablation device 21 CFR 878.4400, Electrosurgical Cutting and Coagulation Device and Accessories General and Plastic Surgery
E. Device Description
The NanoKnife System is a software-controlled low-energy direct-current (LEDC) generator which surgically ablates soft tissue. Included for use with the system are the NanoKnife Single Electrode Probes and optional Probe Spacer. With the NanoKnife System, electrical current is delivered between pairs of probes in a series of pulses. The waveform of the current is adjustable as determined by clinician-chosen parameters. These parameters include volts/cm, pulse length, number of pulses to be delivered between electrode pairs, distance between probes, and the timing mode (90PPM, 240PPM or ECG synchronization). Up to six probes may be placed in an array within the tissue. The array are matched as pairs by the system. When probes are activated via a foot-pedal, the scheduled current is delivered to tissue between subsequent pairs of probes. Soft tissue between the probes is ablated.
4
F. Intended Use and Indications for Use
The intended use of the NanoKnife System is identical to the intended use of the predicate device, the NanoKnife System subject of K102329:
"The NanoKnife System with six outputs is indicated for the surgical ablation of soft tissue. "
The NanoKnife System is used in the same manner as the predicate device, the NanoKnife System subject of K102329.
G. Summary of Similarities and Differences in Technological Characteristics and Performance between the Predicate and Modified Device
The NanoKnife Generator, subject of this 510(k) Premarket Notification, is a modification to the NanoKnife Generator submitted in K102329. The available ablation parameters, pulse amplitude, pulse length, maximum energy per pulse, and energy storage between recharges of the NanoKnife Generator are all identical to the predicate device. The design modifications to the NanoKnife Generator consist of hardware, firmware, software and labeling changes. Table 1 below provides a summary of these changes.
Hardware and Specifications |
---|
Component changes due to availability of components and to improve |
the electromagnetic (EMC)/electromagnetic (EMI) profile of the device |
to comply with IEC 60601-1 3rd ed. standards. |
Increased shelf life specification of Single Electrode Probes to 3 years |
(no design modification or change to functionality) |
Firmware |
Programming and code changes to: |
• eliminate system shutdowns upon detection of over-current |
conditions |
• debug programming (continuous device life-cycle improvement) |
• enhance software diagnostics |
Software |
Programming and code changes to: |
• remove non-English Languages |
• disable radio frequency identification (RFID) functionality |
• enable functions in administrator mode (not available to users) |
• add clearer warning messages to the user when using 240 PPM and |
90 PPM pulse modes |
• debug programming (continuous device life-cycle improvement) |
Labeling |
System Manual Updates - reorganized and revised safety section, |
including expanded discussion of High Current and Over-Current |
conditions |
User Manual - Removed discussion of RFID functions |
User Manual - Add information per IEC 60601-1 3rd ed. |
Pouch/Box Label - Administrative changes |
Table 1. Summary of Design Modifications
5
The NanoKnife Single Electrode Probes and optional Probe Spacer are identical to the NanoKnife Single Electrode Probes and Probe Spacer utilized by the predicate NanoKnife System. Two Single Electrode Probes (15cm and 25cm lengths) are offered with the modified device. The manual actuation, material, tip configuration, and sterilization method of the NanoKnife Single Electrode Probes are all identical to the predicate device.
Furthermore, there have been no changes made to the way ablation procedures will be performed using the NanoKnife System as compared to the predicate device. Users trained in the use of the NanoKnife System predicate device are instructed to confirm that the ablation was successful using standard imaging techniques. Like its predicate device, the NanoKnife System is a tool for surgically ablating soft tissue. Both the predicate device and the NanoKnife System require visual confirmation of ablation using standard imaging techniques (e.g., CT or ultrasound) following the procedure.
H. Performance Data
The modified NanoKnife System Generator was tested per the following to support a determination of substantial equivalence:
- Performance testing, including: ●
- ECG synchronization operation O
- Power supply regulation O
- AC/DC board voltages O
- Charge bank verification O
- Hardware safety measures (i.e., over/under current pulse intervention, overlength pulse, O Field Programmable Gate Array firmware functionality, etc.)
- Voltage and current accuracy O
- Pulse duration O
- Minimum capacitance O
- Pulse amplitude O
- Pulse frequency O
- Pulse intervals O
- O Pulse count
- Maximum energy delivered O
- Emergency Stop Button functionality o
- Ship testing environmental and vibration/handling ●
- Reliability testing
- EMC testing (EN 60601-1-2:2001/A1:2006) ●
- . Electrical safety testing (IEC 60601-1-2:2001/A1:2004)
- Software validation testing .
The test results verify that the NanoKnife System meets all the specified performance specifications and thus, is substantially equivalent to the predicate device.
Additionally, AngioDynamics performed a series of ablation and thermal zone calculations with physical parameters input to the Pennes bioheat model utilizing an industry standard differential equation and finite element analysis tool for physics and biological systems. The results of worst-case modeling indicate that potential thermal ablation volumes lie within the boundaries of electroporation volumes where clinically-relevant input parameters are utilized.
I. Conclusion
The modified NanoKnife System is substantially equivalent to the predicate NanoKnife System (K102329). The design modifications included in this 510(k) Premarket Notification do not affect the cleared intended use or indications for use. Nor do the design modifications alter the fundamental
6
technological characteristics of the predicate or raise new questions of safety and effectiveness. Where changes in technology occur, the results of performance testing confirm the modified NanoKnife System is substantially equivalent to the predicate device.